Christie today announced the launch of the Christie CounterAct line of commercial UV disinfection products with patented Care222 far-UVC light technology for cinemas, theme parks, museums, sports complexes and other indoor spaces.
The Christie fixture uses Ushio’s patented narrowband filtered Care222 excimer lamps that emit far-UVC 222nm light that may also be used while people are present, when used in accordance with specified parameters.
Mass production of the new Christie CounterAct fixture starts in January 2021.
Developed by Christie’s parent company, Ushio Inc., based on technology licensed from Columbia University, the Care222 far-UVC, mercury-free excimer lamp includes a proprietary short pass filter that prevents the emission of longer wavelengths of UV light (230nm and higher) that are capable of penetrating human skin and eyes.
More About Christie CounterAct
Christie CounterAct is a line of fixtures that can be controlled remotely and can be installed on ceilings like a commercial lighting fixture. It is well-suited for use across a wide range of occupied, commercial areas such as entertainment venues, including lobbies, auditoriums, and restrooms, as well as other indoor spaces.
The first Christie CounterAct fixture contains two Care222 excimer far-UVC lamps that reduce pathogens on surfaces of any indoor space. The fixture, with instant on/off at full output power and its Care222 technology lamps, has been shown effective at reducing pathogens in laboratory tests.
The filtered 222nm far-UVC light emitted by Care222 lamps in Christie’s CounterAct fixture, which can operate continuously even when people are present, offers a significant improvement over traditional manual cleaning alone, which requires professional cleaners, and the repeated use of harsh chemicals, in which the results are temporary.
“People are essential to the entertainment industry, and their level of comfort in public venues is paramount to the industry’s success,” said Christie president and COO Zoran Veselic in the company announcement.
“We are very proud to be able to offer this product with Ushio’s Care222 technology to our partners, and we are excited about the possibilities the technology will have in bringing customers back to the places they love, such as movie theaters and theme parks,” he said.
“The fact that far-UVC light – specifically, our new Christie CounterAct far-UVC fixture – can be used in the presence of people is a real differentiating factor,” said Veselic.
“By harnessing these benefits as part of a user-friendly product that can be quickly deployed, we hope to provide a much-needed boost to our partners across the entertainment industry who are currently struggling to attract wary customers,” he said.
